Dianthus Therapeutics | MGTA - Ebitda

Stock Price
86.16
Daily Change
0.82 0.96%
Monthly
-7.26%
Yearly
337.58%
Q2 Forecast
84.43

Dianthus Therapeutics reported $-40.19M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Akebia Therapeutics USD 14.03M 17.19M Mar/2025
Alaunos Therapeutics USD -21.02M 1.33M Mar/2021
Avita Medical AUD -9.69M 12.21M Dec/2025
Celltrion KRW 17.79B 356.77B Dec/2025
Cspc Pharmaceutical CNY 2.19B 21.88M Dec/2024
Deva Holding AS TRY 882.9M 201.7M Sep/2023
Dianthus Therapeutics USD -40.19M 5.36M Sep/2025
Divis Laboratories Ltd INR 8.9B 20M Dec/2025
IQVIA Holdings USD 932M 114M Mar/2026
Kangmei Pharma CNY 17.3M 20.56M Jun/2025
Knight Therapeutics CAD 24.45M 3.46M Dec/2025
Laboratorios Farma EUR 34.94M 102.95M Jun/2025
Malin Corporation EUR -1.1M 200K Dec/2024
Medical Developments International AUD 1.78M 3.78M Dec/2024
Moderna USD -790M 582M Dec/2025
Neuren Pharmaceuticals AUD 11.14M 165.56M Dec/2025
Organigram Holdings CAD 5.26M 884K Dec/2025
Organon & Co USD 415M 32M Mar/2026
Pharma Mar EUR 2.71M 42.25M Mar/2026
Qiagen NV USD 249.69M 56.53M Dec/2025
Revvity USD 272.91M 24M Mar/2026
Sartorius EUR 267.3M 10.1M Mar/2026
Sino Biopharmaceutical CNY 2.59B 1.57B Dec/2024
Tectonic Therapeutic USD -21.18M 365K Dec/2025
Tilray USD 8.36M 1.82M Sep/2025
Viatris USD 1.05B 46.4M Mar/2026
Xeris Pharmaceuticals USD 25.09M 7.67M Dec/2025
Zealand Pharma A/S -727.47M 285.54M Dec/2025
Zhangzhou Pientzehuang Pharmaceutical CNY 882.7M 351.1M Mar/2026